Core Insights - Opus Genetics is advancing its gene therapy pipeline aimed at treating inherited retinal diseases (IRDs) with positive clinical results and new funding opportunities [2][6][17] Financial Performance - As of December 31, 2025, the company reported cash and cash equivalents of $45.1 million, with an additional $25.0 million raised through a private placement, bringing total cash resources to $70.1 million, expected to fund operations into the first half of 2028 [11][12] - License and collaborations revenue for 2025 was $14.2 million, an increase from $11.0 million in 2024, primarily driven by collaboration with Viatris, Inc. [12] - Research and Development (R&D) expenses rose to $30.8 million in 2025 from $26.9 million in 2024, attributed to higher clinical research costs [13] - General and Administrative (G&A) expenses increased to $22.0 million in 2025 from $18.2 million in 2024, mainly due to higher legal and payroll costs [14] - The net loss for 2025 was $49.6 million, a decrease from a net loss of $57.5 million in 2024, reflecting improved financial performance [15] Pipeline Updates - The company is developing OPGx-BEST1 and OPGx-LCA5 gene therapies, with favorable early safety and efficacy data reported for the BEST1 program [3][4][6] - Recruitment is ongoing for the Phase 1/2 trial (BIRD-1) for OPGx-BEST1, with initial data showing no ocular inflammation and early signs of functional vision improvement [7] - Funding has been secured for the OPGx-MERTK program to evaluate its efficacy in treating MERTK-related retinitis pigmentosa [5][8] - The FDA has set a PDUFA date of October 17, 2026, for Phentolamine Ophthalmic Solution 0.75% for presbyopia, with ongoing pivotal Phase 3 trials [6][15] Strategic Developments - The reauthorization of the U.S. Rare Pediatric Disease Priority Review Voucher program is expected to enhance the company's pipeline development in rare inherited retinal diseases [2][6] - The company is positioned to create significant long-term value for shareholders through its capital-efficient operating model and multiple upcoming catalysts [2]
Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update